1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Pet Care Diabetes Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Pet Care Diabetes Drugs Market Analysis and Forecasts, 2017 – 2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Epidemiology of Diabetes in Pets
5.2. Key Industry Events
5.3. COVID-19 Pandemic Impact on Industry
6. Global Pet Care Diabetes Drugs Market Analysis and Forecasts, By Animal Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Animal Type, 2017 – 2031
6.3.1. Cats
6.3.2. Dogs
6.4. Market Attractiveness By Animal Type
7. Global Pet Care Diabetes Drugs Market Analysis and Forecasts, By Product Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product Type, 2017 – 2031
7.3.1. Insulin Drugs
7.3.2. SGLT2 Inhibitors
7.3.3. Others
7.4. Market Attractiveness By Product Type
8. Global Pet Care Diabetes Drugs Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2017 – 2031
8.3.1. Vet Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Others
8.4. Market Attractiveness By End-user
9. Global Pet Care Diabetes Drugs Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Rest of World
9.3. Market Attractiveness By Country/Region
10. North America Pet Care Diabetes Drugs Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Animal Type, 2017 – 2031
10.2.1. Cats
10.2.2. Dogs
10.3. Market Value Forecast By Product Type, 2017 – 2031
10.3.1. Insulin Drugs
10.3.2. SGLT2 Inhibitors
10.3.3. Others
10.4. Market Value Forecast By End-user, 2017 – 2031
10.4.1. Vet Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Others
10.5. Market Value Forecast By Country, 2017 – 2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Animal Type
10.6.2. By Product Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Pet Care Diabetes Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Animal Type, 2017 – 2031
11.2.1. Cats
11.2.2. Dogs
11.3. Market Value Forecast By Product Type, 2017 – 2031
11.3.1. Insulin Drugs
11.3.2. SGLT2 Inhibitors
11.3.3. Others
11.4. Market Value Forecast By End-user, 2017 – 2031
11.4.1. Vet Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Others
11.5. Market Value Forecast By Country, 2017 – 2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Animal Type
11.6.2. By Product Type
11.6.3. By End-user
11.6.4. By Country
12. Rest of World Pet Care Diabetes Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Animal Type, 2017 – 2031
12.2.1. Cats
12.2.2. Dogs
12.3. Market Value Forecast By Product Type, 2017 – 2031
12.3.1. Insulin Drugs
12.3.2. SGLT2 Inhibitors
12.3.3. Others
12.4. Market Value Forecast By End-user, 2017 – 2031
12.4.1. Vet Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Others
12.5. Market Attractiveness Analysis
12.5.1. By Animal Type
12.5.2. By Product Type
12.5.3. By End-user
13. Competition Landscape
13.1. Market Player – Competition Matrix (By Tier and Size of Companies)
13.2. Market Share Analysis By Company (2022)
13.3. Company Profiles
13.3.1. Boehringer Ingelheim International GmbH
13.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.1.2. Product Portfolio
13.3.1.3. Financial Overview
13.3.1.4. SWOT Analysis
13.3.1.5. Strategic Overview
13.3.2. Elanco
13.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.2.2. Product Portfolio
13.3.2.3. Financial Overview
13.3.2.4. SWOT Analysis
13.3.2.5. Strategic Overview
13.3.3. Merck Animal Health
13.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.3.3.2. Product Portfolio
13.3.3.3. Financial Overview
13.3.3.4. SWOT Analysis
13.3.3.5. Strategic Overview
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
